Abionyx Pharma SA (PA:ABNX) — Stock Price

€1.92 EUR
▼ -2.44% today

Abionyx Pharma SA (PA:ABNX) is currently trading at €1.92 EUR, down 2.44% today. Over the past 52 weeks, shares have ranged between €1.77 and €5.00. This page tracks Abionyx Pharma SA's live share price on the PA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Abionyx Pharma SA (ABNX) total market value.

Abionyx Pharma SA (ABNX) Stock Price Chart — Daily History & Trading Volume

The chart below tracks Abionyx Pharma SA's daily closing share price and trading volume on the PA exchange over the past year, giving a clear view of recent price momentum and liquidity.

Abionyx Pharma SA Income Statement — Revenue, Profit & Earnings by Year

Abionyx Pharma SA's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.

Fiscal Year 20242023202220212020
Total Revenue €4.60 Million €4.64 Million €5.25 Million €675.00K €0.00
Cost of Revenue €3.70 Million €4.02 Million €4.62 Million €416.00K €80.00K
Gross Profit €844.00K €618.00K €636.00K €259.00K €-80.00K
Research & Development €2.99 Million €2.90 Million €2.56 Million €5.68 Million €2.31 Million
SG&A €1.29 Million €1.11 Million €1.19 Million €503.00K €562.00K
Total Operating Expenses €5.31 Million €4.03 Million €4.75 Million €6.21 Million €3.50 Million
Operating Income €-5.57 Million €-3.41 Million €-4.11 Million €-5.95 Million €-3.58 Million
EBITDA €-4.93 Million €-4.84 Million €-4.01 Million €-7.42 Million €-2.33 Million
EBIT €-5.41 Million €-4.68 Million €-4.14 Million €-7.54 Million €-2.41 Million
Interest Expense €61.00K €19.00K €240.00K €124.00K €95.00K
Income Before Tax €-5.47 Million €-3.52 Million €-4.21 Million €-5.82 Million €-2.50 Million
Income Tax Expense €-1.07 Million €-1.38 Million €-1.46 Million €8.00K €-617.00K
Net Income €-4.40 Million €-3.52 Million €-4.21 Million €-5.82 Million €-1.89 Million

Abionyx Pharma SA Balance Sheet — Assets, Liabilities & Shareholder Equity

The balance sheet below summarizes Abionyx Pharma SA's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.

Fiscal Year 20242023202220212020
Total Assets €13.45 Million €14.83 Million €15.82 Million €21.83 Million €10.29 Million
Total Current Assets €5.86 Million €6.89 Million €7.57 Million €13.01 Million €10.03 Million
Cash & Equivalents
Short-term Investments €50.00K €-41.00K €-31.00K €0.00
Net Receivables €2.29 Million €2.50 Million €1.30 Million €1.57 Million €50.00K
Inventory €211.00K €221.00K €147.00K €177.00K €38.00K
Property, Plant & Equipment €1.98 Million €2.21 Million €2.56 Million €3.07 Million €115.00K
Goodwill €5.38 Million €5.38 Million €5.38 Million €5.38 Million €0.00
Total Liabilities €6.03 Million €6.91 Million €8.65 Million €11.15 Million €3.66 Million
Total Current Liabilities €3.71 Million €3.92 Million €5.09 Million €6.75 Million €3.60 Million
Long-term Debt €611.00K €1.10 Million €1.42 Million €1.65 Million €0.00
Net Debt €-137.00K €-714.00K €-33.00K €-2.98 Million €-9.13 Million
Total Stockholder Equity €7.42 Million €7.92 Million €7.17 Million €10.68 Million €6.63 Million
Retained Earnings €1.00K €-3.52 Million €-4.21 Million €-5.82 Million €-1.89 Million

Abionyx Pharma SA Cash Flow Statement — Operating, Investing & Financing Activities

This cash flow statement breaks down how Abionyx Pharma SA generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.

Fiscal Year 20242023202220212020
Operating Cash Flow €-3.60 Million €-3.70 Million €-3.36 Million €-6.69 Million €-599.00K
Capital Expenditures €76.00K €130.00K €175.00K €166.00K €148.00K
Free Cash Flow €-3.60 Million €-3.83 Million €-3.53 Million €-6.86 Million €-747.00K
Investing Cash Flow €-100.00K €-130.00K €-175.00K €1.34 Million €-125.00K
Financing Cash Flow €2.80 Million €3.89 Million €-194.00K €3.97 Million €1.55 Million
Dividends Paid €3.97 Million €1.55 Million
Stock-Based Compensation €626.00K €20.00K €506.00K €815.00K €98.00K
Depreciation €135.00K €153.00K €135.00K €119.00K €22.00K
Change in Cash €-902.00K €58.00K €-3.73 Million €-1.38 Million €823.00K

Abionyx Pharma SA Earnings History — EPS Actual vs. Analyst Estimates

Track Abionyx Pharma SA's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.

Report Date EPS Actual EPS Estimate Surprise
Mar 04, 2026
Nov 25, 2025 0.00 0.00
Sep 25, 2025 -0.03
May 28, 2025 0.00 0.00
Mar 17, 2025 -0.07 0.00
Nov 14, 2024 0.00 0.00
Sep 26, 2024 0.00 0.00
May 16, 2024 0.00 0.00